Nous avons participé à l’élaboration d’une stratégie nationale concernant les médicaments à cout élevé pour maladies rares.

This entry was posted on Samedi, juillet 25th, 2020 at 6:25 pm and is filed under . You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

Comments are closed.